| [iito] Business Intelligence. (May 2019). "Special Feature: What Does [iito] Stand For? A Powerful Business Database System, based on Property Rights Theory and Institutional Economics = [i]nstitutions [i]nformation [t]echnologies [o]rganisation!". Breme |
2019-05-30 |
| [iito] Business Intelligence. (April 2019). "Special Feature: [iito] Relaunches Life-Sciences-UK.com & Life-Sciences-France.com". Bremen. |
2019-04-17 |
| [iito] Business Intelligence. (April 2019). "Special Feature: [iito] Reaches New Milestone – Now more than 9,900 European Life Science Deals Available at Life-Sciences-Europe.com". Bremen. |
2019-04-26 |
| [iito] Business Intelligence. (9/29/11). "[iito]view – E-mail Interview with Pierre Legrain, Vice President of HUPO". Bremen. |
2011-09-29 |
| [iito] Business Intelligence. (9/15/10). "Press Release: [iito] Announces Milestones for Mass Spectrometry Web Portal »Mass-Spec-Capital.com«. Opens Newsletter Archives – Launches Own Editorial Content". Bremen. |
2010-09-15 |
| [iito] Business Intelligence. (7/8/19). "Press Release: [iito] Launches Life-Sciences-Benelux.com
& Life-Sciences-Scandinavia.com". Bremen. |
2019-07-08 |
| [iito] Business Intelligence. (7/1/19). "Press Release: Worldwide First! [iito] Does Away with All Tracking Cookies and Third Party Cookies". Bremen. |
2019-07-01 |
| [iito] Business Intelligence. (5/23/11). "Press Release: Launch of Life-Sciences-Germany.com – English-language Doorway to Life Sciences in German-speaking Europe". Bremen. |
2011-05-23 |
| [iito] Business Intelligence. (5/20/10). "Press Release: [iito] Launches Free Mass Spectrometry Newsletter. Premier Issue Right in Time for ASMS 2010 Meeting in Salt Lake City – New Service Is Based on the Web Portal www.Mass-Spec-Capital.com". Bremen. |
2010-05-20 |
| [iito] Business Intelligence. (3/5/10). "Press Release: Launch of New Mass Spectrometry Web Portal – Mass-Spec-Capital.com". Bremen. |
2010-03-05 |
| [iito] Business Intelligence. (3/24/11). "Press Release: [iito] Business Intelligence Enters Social Media with an Initial Focus on Twitter. Strategic Move Positions [iito] in the Up-to-the-Minute News Market for Mass Spectrometry as well as German and Eu |
2011-03-24 |
| [iito] Business Intelligence. (12/9/15). "Press Release: Life-Sciences-UK.com Launches Today. New Business Web Portal for the UK and Irish Life Sciences Targets Decision Makers World-wide". Bremen & London. |
2015-12-09 |
| [iito] Business Intelligence. (11/7/11). "Press Release: [iito] Completes Online B2B Offering with Launch of Free Newsletter for the European Life Sciences. Premier Issue of the [LSE] Newsletter Published Today". Bremen. |
2011-11-07 |
| [iito] Business Intelligence. (11/11/19). "Press Release: [iito] Launches Transatlantic Life Sciences Business Portal at BIO-Europe". Bremen & Hamburg. |
2019-11-11 |
| [iito] Business Intelligence. (10/6/11). "Press Release: [iito] Launches Free Monthly Newsletter for the Life Sciences in Germany, Austria and Switzerland. Premier Issue of the [LSG] Newsletter Published Today". Bremen. |
2011-10-06 |
| [iito] Business Intelligence. (10/5/15). "Press Release: Life-Sciences-France.com Launches Today. New Business Web Portal for the French Life Sciences Targets Decision Makers Worldwide". Bremen & Paris. |
2015-10-05 |
| [iito] Business Intelligence. (10/4/12). "Press Release: [iito] Is Putting Privacy and Content First. Free [iito] Web Offerings Target Senior-level Managers in the Worldwide Life Sciences Industry". Bremen. |
2012-10-04 |
| [iito] Business Intelligence. (10/31/18). "Press Release: [iito] Discontinues Life-Sciences-Spain.com. All Data Will Still Be Available at Life-Sciences-Europe.com". Bremen. |
2018-10-31 |
| [iito] Business Intelligence. (10/11/11). "Press Release: Life-Sciences-Europe.com Launches Today. Business Web Portal for the European Life Sciences". Bremen. |
2011-10-11 |
| [iito] Business Intelligence. (1/11/19). "Press Release: [iito] Discontinues Life-Sciences-UK.com
and Life-Sciences-France.com. All Data Will Still Be Available at Life-Sciences-Europe.com". Bremen. |
2019-01-11 |
| Zytoprotec GmbH. (1/29/13). "Press Release: Zytoprotec Raises EUR 2 Million in Financing from Baxter Ventures". Vienna. |
2013-01-29 |
| Zivak Technologies. (10/3/13). "Press Release: Introduction of SPE9600 Automated 96-Well-Plate SPE System at Medica 2013 Fair". |
2013-10-03 |
| Zivak Technologies. (10/2/13). "Press Release: ZinMass Clinical LC-MS/MS Analyzer Will Be Exhibited at Medica 2013". |
2013-10-02 |
| Zeltia S.A.. (9/15/15). "Press Release: PharmaMar Opens New Affiliate in UK". Madrid. |
2015-09-15 |
| Zeltia S.A.. (11/7/12). "Press Release: PharmaMar Germany Commences Commercial Activity". Madrid. |
2012-11-07 |
| Zelluna Immunotherapy AS. (6/25/19). "Press Release: Zelluna Immunotherapy Appoints Jens-Peter Marschner as Chief Medical Officer". Oslo. |
2019-06-25 |
| Zellkraftwerk. (1/3/13). "Press Release: Zellkraftwerk Announces Early Access Program. Select Drug Developers to Obtain Pre-release Access to Groundbreaking Cellular Biomarker Discovery Platform". Hannover. |
2013-01-03 |
| Zedira GmbH. (9/22/15). "Press Release: Cooperation between Zedira and Cardiff University. Transglutaminase 6 Is the Focus of New Research into Ataxia". |
2015-09-22 |
| Zedira GmbH. (7/1/16). "Press Release: Dr. Falk Pharma GmbH and Zedira Enter a Phase 1b Clinical Trial for a Celiac Disease Drug". Freiburg & Darmstadt. |
2016-07-01 |
| Zedira GmbH. (6/25/12). "Press Release: Zedira, Dr. Falk Phama and the University of Mainz Hospital, which Together Comprise a Flagship Project of the CI3 Excellence Cluster, Are to Receive Subsidy Funding for Clinical Development of a Celiac Disease Dru |
2012-06-25 |
| Zedira GmbH. (5/2/17). "Press Release: Dr. Falk Pharma and Zedira Announce Completion of Phase 1b Clinical Trial of ZED1227 for the Treatment of Celiac Disease and Move on to Proof of Concept Study". Freiburg & Darmstadt. |
2017-05-02 |
| Zedira GmbH. (4/26/18). "Press Release: Dr. Falk Pharma and Zedira Announce Start of the Phase 2a Proof of Concept Study of ZED1227 for the Treatment of Celiac Disease". Freiburg & Darmstadt. |
2018-04-26 |
| Zedira GmbH. (3/2/15). "Press Release: Dr. Falk Pharma and Zedira Enter Phase I Clinical Trials for a Celiac Disease Drug". Freiburg & Darmstadt. |
2015-03-02 |
| Zedira GmbH. (2/3/15). "Press Release: Zedira Receives further Funding to Develop Factor XIIIa-blockers for Safe Anticoagulation". Darmstadt. |
2015-02-03 |
| Zedira GmbH. (11/30/16). "Press Release: Zedira Receives Funding by the German Government for the Development of Transglutaminase Inhibitors for the Treatment of Diabetic Nephropathy". Darmstadt. |
2016-11-30 |
| Zedira GmbH. (10/20/15). "Press Release: Zedira, Dr. Falk Pharma and the University of Mainz Hospital, which Together Comprise a Flagship Project of the Ci3 Leading-edge Cluster, Are to Receive Additional Subsidy Funding for Clinical Development of a Cel |
2015-10-20 |
| Zealand Pharma A/S. (9/3/13). "Press Release: Zealand Appoints New Chief Scientific Officer. Dr Torsten Hoffmann Joins from Roche". Copenhagen. |
2013-09-03 |
| Zealand Pharma A/S. (7/3/17). "Press Release: Zealand Initiates First Phase 3 Trial with Dasiglucagon for the Treatment of Severe Hypoglycemia in Diabetes". Copenhagen. |
2017-07-03 |
| Zealand Pharma A/S. (7/28/14). "Press Release: Zealand and Boehringer Ingelheim Sign Second Collaboration Agreement to Advance Novel Peptide Medicines". Copenhagen & Ingelheim. |
2014-07-28 |
| Zealand Pharma A/S. (6/16/11). "Press Release: Zealand Pharma and Boehringer Ingelheim Enter into a License and Collaboration Agreement to Advance Novel Compounds to Treat Type-2 Diabetes and Obesity". Copenhagen & Ingelheim. |
2011-06-16 |
| Zealand Pharma A/S. (10/9/15). "Press Release: Zealand Meets Development Milestone in Collaboration with Boehringer Ingelheim". Copenhagen. |
2015-10-09 |
| Zavante Therapeutics, Inc.. (3/30/16). "Press Release: Zavante Therapeutics Closis $45 Million Series A Financing in Support of U.S. Development for a First-in-Class Injectable Antibiotic". San Diego, CA. |
2016-03-30 |
| Zavante Therapeutics, Inc.. (10/9/15). "Press Release: Zavante Announces New Company Formation and Initial Financing". San Diego, CA. |
2015-10-09 |
| Zambon Group. (7/25/19). "Press Release: Zambon Completes Transformational Acquisition of Breath Therapeutics". Milan. |
2019-07-25 |
| Yumab GmbH. (7/22/19). "Press Release: Yumab Announces New Research and Collaboration Agreement with Merck". Braunschweig. |
2019-07-22 |
| Yukin Therapeutics S.A.S.. (6/4/19). "Press Release: Yukin Therapeutics Raises €3.3 million to Develop New Cancer Treatments". Sophia Antipolis. |
2019-06-04 |
| Ysios Capital. (10/18/16). "Press Release: Ysios Capital Raises €126,4 m ($140 m) for Its Second Fund, Ysios Biofund II Innvierte". Barcelona. |
2016-10-18 |
| Ysios Capital Partners. (09/13/2011). "Press Release: Ysios Capital Partners Leads €29.2million Series D Financing of AM-Pharma". Barcelona. |
2011-09-13 |
| Xoma Corporation. (8/25/17). "Press Release: Xoma Announces Transformational License Agreements for Gevokizumab and Its IL-1 beta Intellectual Property Portfolio". Berkeley, CA. |
2017-08-25 |
| Xlife Sciences AG. (11/4/19). "Press Release: Xlife Siences AG. New Project in the Portfolio". Zurich. |
2019-11-04 |
| XL-protein GmbH. (7/26/17). "Press Release: Jazz Pharmaceuticals and XL-protein GmbH Enter Into a License Agreement on PASylation Technology to Develop Long-Acting Asparaginase Product Candidates". Freising. |
2017-07-26 |
| XL-protein GmbH. (6/25/13). "Press Release: XL-protein and Generium Sign Broad Therapeutic License and Collaboration Agreement to Develop PASylated Therapeuticas for the Russian Federation". Freising & Moscow. |
2013-06-25 |
| XL-protein GmbH. (4/18/13). "Press Release: High Yield with ESETEC and PASylation. Wacker Biotech and XL-protein Produce More than Four Grams per Liter of Fab Antibody Fragment with Prolonged Plasma Half-life". Munich, Jena & Freising. |
2013-04-18 |
| XL-protein GmbH. (2/12/15). "Press Release: XL-protein Signs Licensing Agreement with MSD Animal Health to Develop Biopharmaceuticals Using its PASylation Technology". Freising. |
2015-02-12 |
| XL-protein GmbH. (10/21/14). "Press Release: Yeda and XL-protein Sign Business Collaboration Agreement to Commercialize PASylated Interferon Superagonist". Freising & Rehovot. |
2014-10-21 |
| XL-protein GmbH. (1/9/18). "Press Release: Horizon Pharma plc and XL-protein GmbH Have Entered Into a Collaboration Agreement on a Potential Next-Generation Biologic for Uncontrolled Gout Using PASylation® Technology". Freising. |
2018-01-09 |
| Xigen S.A.. (1/5/17). "Press Release: Xigen’s Brimapitide, an Innovative JNK Inhibitor, Delivers Positive Phase II Results in Inflammatory Eye Disease". Geneva. |
2017-01-05 |
| Xenikos B.V.. (5/24/16). "Press Release: Xenikos B.V. to Introduce Immunotherapy T-Guard to Potential Pharmaceutical Partners at BIO International Convention 2016". Nijmegen. |
2016-05-24 |
| Xencor, Inc.. (4/4/12). "Press Release: Xencor Receives Second Milestone Payment from Boehringer Ingelheim under Antibody Technology License Agreement". Monrovia, CA. |
2012-04-04 |
| Xencor, Inc.. (2/5/19). "Press Release: Xencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with Genentech". Monrovia, CA. |
2019-02-05 |
| Xencor, Inc.. (1/7/19). "Press Release: Xencor Regains ex-U.S. Commercial Rights to XmAb®13676, CD20 x CD3 Bispecific Antibody". Monrovia, CA. |
2019-01-07 |
| Xeltis. (12/2/14). "Press Release: Xeltis Closes Euro 27 Million / USD 34 Million Series B Financing". Zürich. |
2014-12-02 |
| Xeltis AG. (2/2/16). "Press Release: Xeltis Appoints New CFO". |
2016-02-02 |
| Xeltis AG. (12/17/15). "Press Release: Xeltis Extends Series B Financing to €30M, Signing off Transformational Year". Zurich. |
2015-12-17 |
| Xeltis AG. (11/15/17). "Press Release: Xeltis Closes €45 Million in Oversubscribed Series C Financing to Advance Aortic and Pulmonary Valve Programs". Zurich & Eindhoven. |
2017-11-15 |
| Xeltis AG. (1/31/17). "Press Release: FDA Gives Xeltis Go Ahead to Begin Trials in the USA". |
2017-01-31 |
| X-Biotix Therapeutics, Inc.. (7/1/19). "Press Release: X-Biotix Therapeutics Joins Antimicrobials Working Group". Washington, DC. |
2019-07-01 |
| WuXi AppTec. (4/15/16). "Press Release: WuXi AppTec Acquires Crelux". Munich. |
2016-04-15 |
| Wise S.r.l.. (5/25/17). "Press Release: Wise Srl Raises EUR 6.5 Million for Clinical Validation of Novel Neuroelectrodes for Brain Monitoring and Spinal Cord Stimulation". Milan & Berlin. |
2017-05-25 |
| Wilex AG. (9/6/13). "Press Release: Nuclea Biotechnologies Inc. Acquires Wilex Inc. and Extends Their Cooperation with Wilex AG. Nuclea Purchased All Shares of Wilex Inc. (Oncogene Science)". Munich & Pittsfield, MA & Cambridge, MA. |
2013-09-06 |
| Wilex AG. (9/27/16). "Press Release: Subsidiary Heidelberg Pharma Contracts Suisse CDMO Celonic for Antibody Cell Line Development and Antibody Production". Munich. |
2016-09-27 |
| Wilex AG. (9/2/13). "Press Release: Wilex Subsidiary Heidelberg Pharma Signs License Agreement for the Development of Antibody Targeted Amanitin Conjugates (ATACs) with Roche". Munich. |
2013-09-02 |
| Wilex AG. (9/19/16). "Press Release: Wilex AG – Subsidiary Heidelberg Pharma Signs Option Agreement with Max Delbrück Center". Munich. |
2016-09-19 |
| Wilex AG. (8/7/13). "Press Release: Wilex Starts Clinical Phase I Trial with PI3K Inhibitor WX-037". Munich. |
2013-08-07 |
| Wilex AG. (8/4/10). "Press Release: Wilex AG Successfully Completes Rights Issue". Munich. |
2010-08-04 |
| Wilex AG. (8/17/10). "Press Release: Wilex AG. Mandatory Takeover Offer from dievini Hopp BioTech Has Ended". Munich. |
2010-08-17 |
| Wilex AG. (8/12/15). "Press Release: Wilex AG Announces Discontinuation of Collaboration between Its Subsidiary Heidelberg Pharma and Roche [Ad-hoc release pursuant to § 15 Wertpapierhandelsgesetz (German Securities Trading Act)]". Munich. |
2015-08-12 |
| Wilex AG. (7/29/10). "Press Release: Wilex AG Recommends Shareholders Not to Accept the Mandatory Offer of dievini Hopp BioTech holding GmbH % Co. KG". Munich. |
2010-07-29 |
| Wilex AG. (7/2/13). "Press Release: Burrill Securities Supports Wilex in Exploring Financing Partners". Munich. |
2013-07-02 |
| Wilex AG. (7/19/10). "Press Release: Wilex AG Resolves Rights Issue Using Authorised Capital". Munich. |
2010-07-19 |
| Wilex AG. (7/15/14). "Press Release: Wilex Publishes Half-yearly Financial Report 2014". Munich. |
2014-07-15 |
| Wilex AG. (7/15/14). "Press Release: Wilex AG Successfully Completes Capital Reduction. Reverse 4:1 Share Split Reduces Number of Outstanding Shares from 31.3 Million to 7.8 Million". Munich. |
2014-07-15 |
| Wilex AG. (7/15/10). "Press Release: Wilex AG Receives Tender Offer for a Mandatory Takeover Bid by dievini Hopp BioTech holding". Munich. |
2010-07-15 |
| Wilex AG. (7/14/15). "Press Release: Wilex Publishes Half-yearly Financial Report". Munich. |
2015-07-14 |
| Wilex AG. (7/13/17). "Press Release: Wilex Reports on First Half-year". Munich. |
2017-07-13 |
| Wilex AG. (7/12/12). "Press Release: Wilex Announces Results of Successful First Half Year 2012". Munich. |
2012-07-12 |
| Wilex AG. (7/11/13). "Press Release: Wilex Publishes Half-yearly Financial Report 2013". Munich. |
2013-07-11 |
| Wilex AG. (7/10/13). "Press Release: UCB Gets Access to Rights for an Antibody Programme from Wilex for Non-oncology Indications". Munich & Brussels. |
2013-07-10 |
| Wilex AG. (6/2/16). "Press Release: Wilex AG Announces Change on the Executive Management Board". Munich. |
2016-06-02 |
| Wilex AG. (6/19/17). "Press Release: Wilex Subsidiary Heidelberg Pharma Signs Exclusive Multi-target Research Agreement with Takeda for the Development of Antibody Targeted Amanitin Conjugates". Munich. |
2017-06-19 |
| Wilex AG. (6/14/12). "Press Release: Mesupron Met Its Primary Objective of Demonstrating Efficacy in the Proof of Concept Phase II Breast Cancer Trial". Munich. |
2012-06-14 |
| Wilex AG. (5/3/10). "Press Release: Final Phase II Data of Mesupron Confirm Impressive Increase in Overall Survival of Patients with Pancreatic Cancer". Munich. |
2010-05-03 |
| Wilex AG. (4/8/15). "Press Release: Wilex AG Successfully Completes Rights Issue". Munich. |
2015-04-08 |
| Wilex AG. (4/25/16). "Press Release: Wilex AG Successfully Completes Capital Increase". Munich. |
2016-04-25 |
| Wilex AG. (4/24/17). "Press Release: Wilex AG Plans Rights Issue Using Authorised Capital. Ad-hoc release [Not for distribution, publication or transmission in the USA, Canada, Japan and Australia]". Munich. |
2017-04-24 |
| Wilex AG. (4/14/14). "Press Release: Wilex Published 3-Month Financial Reports 2014". Munich. |
2014-04-14 |
| Wilex AG. (4/14/10). "Press Release: Wilex Publishes 3-Month Financial Report 2010 and Reports Improved Results for the Period". Munich. |
2010-04-14 |
| Wilex AG. (4/14/10). "Press Release: Presentation 3-Month Financial Report. 14 April 2010". Munich. |
2010-04-14 |
| Wilex AG. (4/12/17). "Press Release: Interim Management Statement on the First Three Months of 2017". Munich. |
2017-04-12 |
| Wilex AG. (4/12/12). "Press Release: Wilex Publishes Financial Report for the First Quarter of 2012. Rights Issue Successfully Concluded – Process for Final Analysis of Rencarex Started – Revenue and Earnings Improved". Munich. |
2012-04-12 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
Source
![Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px](/banner/iito-20190621-650-089-life-sciences-asia.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
